Barclays raised the firm’s price target on Insulet (PODD) to $316 from $301 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as “impressive.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet Corporation Reports Strong Q3 2025 Results
- Insulet’s Earnings Call: Record Growth and Strategic Expansion
- Insulet’s Strong Sales and Strategic Growth Drive Buy Rating
- Insulet price target raised to $400 from $375 at Jefferies
- Insulet’s Strong Financial Performance and Growth Prospects Earn Buy Rating from Analyst